Infertility

Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast

Retrieved on: 
Thursday, April 4, 2024

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, and RESOLVE : The National Infertility Association today announced a series of nationwide events to commemorate National Infertility Awareness Week (April 21-27, 2024).

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, and RESOLVE : The National Infertility Association today announced a series of nationwide events to commemorate National Infertility Awareness Week (April 21-27, 2024).
  • "National Infertility Awareness Week sheds light on the profound impact of infertility, promoting compassion, empathy, and solidarity for the countless individuals struggling to build their family," said Pete Anevski, CEO of Progyny.
  • This will be the third consecutive year the Empire State Building will be lit to support those faced with infertility.
  • "Being an advocate for others navigating their journey, I am deeply honored to participate in National Infertility Awareness Week alongside Progyny and RESOLVE,” says Iskra Lawrence.

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024

ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.

Key Points: 
  • ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corporate update.
  • Following FDA clearance of FemaSeed, the Company’s revolutionary approach to artificial insemination, Femasys announced completion of enrollment in pivotal trial in support of commercial launch
    Appointed Richard Spector as Chief Commercial Officer and James Liu, M.D.
  • Notably, the majority of women who became pregnant did so after the first FemaSeed procedure,” said Femasys’ CEO Kathy Lee-Sepsick.
  • “Our focus is now on executing on commercialization of FemaSeed and our other available products, as well as advancing the clinical pivotal trial for FemBloc.

Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter and Year Ended December 31, 2023

Retrieved on: 
Wednesday, March 27, 2024

Results of Operations for the Year ended December 31, 2023

Key Points: 
  • Results of Operations for the Year ended December 31, 2023
    Hamilton Thorne sales increased 16% to $67,225,476 for the year-ended December 31, 2023, an increase of $9,047,409 from $58,178,067 during the previous year.
  • Consumable sales in 2023 outpaced the Company’s overall growth despite being affected by the recall of certain products by one of the Company’s contract manufacturers.
  • We are expecting first quarter 2024 reported revenues of between $19.0 to 19.4M, with organic growth for the quarter of approximately 8%.
  • Financial Statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.

Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

Retrieved on: 
Tuesday, April 9, 2024

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd .
  • Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.
  • Dysfunctional cilia can cause blindness, deafness, chronic respiratory infections, kidney disease, heart disease, infertility, obesity and diabetes.
  • In recent years, Charles River has significantly broadened its cell and gene therapy portfolio to simplify complex supply chains and meet the growing demand for plasmid DNA, viral vector, and cell therapy services.

Social media will tell you birth control causes mental health issues, weight gain and infertility – here are the facts

Retrieved on: 
Tuesday, April 9, 2024

Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.

Key Points: 
  • Some women are reportedly even stopping their birth control as a result of misleading posts they’ve seen on TikTok and Instagram.
  • These three common misconceptions about birth control are cropping up online and need to be put in context:

1. Contraception causes depression

  • Countless videos on social media discuss the effect hormonal contraceptives have on mental health – with some creators claiming birth control causes mood changes and even depression.
  • Although there’s some correlation between mental health and some forms of contraception, there are many factors at play.
  • The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.
  • The evidence suggests depression is more common in adolescent girls – and diminishes after the first two years of taking these forms of birth control.
  • At present, there’s little conclusive evidence that contraception (both hormonal and non-hormonal types) cause mental health problems.

2. Contraception causes weight gain

  • Another common social media claim is that birth control causes weight gain.
  • There is one form of contraception that is linked to weight gain.
  • The Depo-Provera injection, which is administered every 12 weeks, has been proved to cause weight gain.


This weight gain may be due to the progesterone in the shot, which can cause people to feel hungrier – potentially leading to overeating and weight gain. If you’re concerned about potential weight gain, the injection is not the only form of contraception available. Other forms of hormonal and non-hormonal contraceptives have not been shown to affect your weight.

3. Birth control lowers your fertility

  • Another common claim on social media is that birth control causes fertility issues.
  • Research shows hormonal contraceptives have no affect on fertility.
  • Again, evidence shows that IUDs pose no risk to fertility.
  • A systematic review reports no specific differences in fertility between hormonal and non-hormonal IUDs.


Christopher O'Sullivan does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Retrieved on: 
Thursday, March 21, 2024

Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually TODAY, March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Retrieved on: 
Wednesday, March 20, 2024

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces topline data from its FemaSeed Localized Directional Insemination for artificial insemination pivotal trial (NCT04968847). The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility. FemaSeed, engineered to enhance fertilization by precisely delivering sperm into the fallopian tube, the site of conception, demonstrated 24% of women became pregnant after FemaSeed with severe male factor (1 million to 20 million total motile sperm count (TMSC)). In contrast, a 6.7% pregnancy rate by cycle was described in the literature for intrauterine insemination (IUI) with male factor (greater than 1 million TMSC).1 Although permitted to have multiple FemaSeed attempts, the majority of women who became pregnant did so after the first FemaSeed procedure. The poor IUI pregnancy rates for this infertility segment usually necessitates assisted reproductive approaches, such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Key Points: 
  • The trial investigated its FemaSeed product in women with a variety of infertility factors with the primary efficacy analysis focused on the severe male factor infertility.
  • “These impressive topline results for our now FDA-cleared FemaSeed, demonstrate significant progress in the treatment of infertility, while confirming its safety profile.
  • “The pivotal trial amassed substantial prospective data in support of the safety and efficacy of FemaSeed as a groundbreaking advancement in artificial insemination.
  • The pivotal trial was concluded prior to completing full enrollment due to Femasys receiving FDA clearance for FemaSeed under the 510(k) pathway in September 2023.

TLI Investigator Dr. Wei Yan Named Editor-in-Chief of the Andrology Journal

Retrieved on: 
Monday, March 18, 2024

Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.

Key Points: 
  • Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.
  • With over 160 peer-reviewed publications and numerous awards, Dr. Yan is a committed researcher and educator.
  • Dr. Yan's vision for Andrology is to enhance its global influence and implement innovative strategies.
  • His plans include prioritizing cutting-edge reviews, rewarding high-quality contributions, and fostering the next generation of researchers through the Trainee Reviewer Program.

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Retrieved on: 
Wednesday, March 13, 2024

ATLANTA, March 13, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces it will participate in a Fireside Chat with Jones Trading Analyst Catherine Novack to discuss the current treatment landscape for infertility treatment in women. Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.

Key Points: 
  • Those interested in attending the event, which will be held virtually on March 21, 2024 at 1PM ET, may register here.
  • will focus on the current treatment options in the infertility services market, including Femasys’ FDA-authorized FemaSeed device for intratubal insemination.
  • Ms. Lee-Sepsick is the founder of Femasys and has nearly three decades of experience as a senior executive in the medical technology industry.
  • She is the lead inventor of the technologies at Femasys and remains committed to advancing much needed technology in women’s health.

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus